贝伐珠单抗联合TC方案治疗晚期卵巢癌患者血清AFP、CA125及远期预后的影响  

Effects of Bevacizumab Combined with TC Regimen on Serum AFP,CA125 and Long-term Prognosis of Patients with Advanced Ovarian Cancer

作　　者：张善存 张江霞 王云龙 ZHANG Shancun;ZHANG Jiangxia;WANG Yunlong(Nanyang Nanshi Hospital,Nanyang,473000)

机构地区：[1]南阳南石医院,473000

出　　处：《实用癌症杂志》2021年第6期1000-1003,共4页The Practical Journal of Cancer

摘　　要：目的探讨贝伐珠单抗(BEV)联合紫杉醇与卡铂(TC)方案治疗晚期卵巢癌患者的疗效及其对血清甲胎蛋白(AFP)、癌胚抗原-125(CA125)及远期预后的影响。方法选取卵巢癌患者100例,将其随机均分为观察组(n=50)和对照组(n=50),比较两组临床疗效,观察两组治疗前后白细胞介素-6(IL-6)与血管内皮生长因子(VEGF)、AFP及CA125水平变化,比较两组远期疗效及不良反应。结果经秩和检验及卡方检验比较,观察组总缓解率(84.00%)显著高于对照组(60.00%)(P<0.05),临床疗效优于对照组(P<0.05)。治疗后观察组血清IL-6、VEGF水平及血清AFP、CA125水平均显著优于对照组(P<0.05)。观察组1年及2年生存率显著优于对照组,两组不良反应发生率比较差异无统计学意义(P>0.05)。结论BEV联合TC方案应用于晚期卵巢癌的治疗效果佳,能有效缓解炎症,抑制肿瘤生长,延长生存时间。Objective To explore the curative effect of bevacizumab(BEV)combined with taxol-carboplatin(TC)regimen on patients with advanced ovarian cancer and its influences on serum alpha-fetoprotein(AFP),carcinoembryonic antigen-125(CA125)and long-term prognosis.Methods A total of 100 ovarian cancer patients were enrolled.They were randomly divided into the observation group(n=50)and the control group(n=50).The clinical curative effect was compared between the 2 groups.The changes in levels of interleukin-6(IL-6),vascular endothelial growth factor(VEGF),AFP and CA125 before and after treatment in both groups were observed.The long-term curative effect and the incidence of side effects were compared between the 2 groups.Results The rank sum test and chi-square test showed that the total remission rate in the observation group was significantly higher than that in the control group(84.00%vs 60.00%)(P<0.05),and clinical curative effect was better than that in the control group(P<0.05).After treatment,levels of serum IL-6,VEGF,AFP and CA125 in observation group were significantly better than those in the control group(P<0.05).The 1-year and 2-year survival rates in observation group were significantly better than those in the control group.There was no significant difference in the incidence of side effects between the 2 groups(P>0.05).Conclusion The curative effect of BEV combined with TC regimen is good on advanced ovarian cancer,which can effectively relieve inflammation,inhibit tumor growth,and prolong survival time.

关 键 词：贝伐珠单抗 TC方案 晚期卵巢癌 AFP CA125 预后 

分 类 号：R737.31[医药卫生—肿瘤]